{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5"},{"groupId":"OG001","value":"92.5"},{"groupId":"OG002","value":"82.5"}]}],"title":"Q3. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q3. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q3. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"15.0"}]}],"title":"Q3. Answer: Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9"},{"groupId":"OG001","value":"93.8"},{"groupId":"OG002","value":"80.0"}]}],"title":"Q4. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Q4. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"5.0"}]}],"title":"Q4. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"15.0"}]}],"title":"Q4. Answer: Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Questions 3 and 4: \"Looking back over the Perjeta-Herceptin treatment sessions, please indicate based on your opinion which administration method: Q3. Was quickest from start to end of preparation to finish of administration (excluding observation period)?; Q4. Required less resource use for preparation and administration, for example nursing time, facility costs, equipment etc?\" The three available response options were: P+H IV, FDC SC, and No Difference.","groups":[{"description":"This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Healthcare Professionals"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 6 (each cycle is 21 days)","title":"Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Time/Resource Use of Each Study Regimen, Questions 3 and 4 of the HCPQ - Drug Preparation Room","type":"SECONDARY","unitOfMeasure":"Percentage of HCPs"}